Cargando…
The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
Evacetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor currently being evaluated in a late-stage cardiovascular outcome trial. Using population-based models, we analyzed evacetrapib concentration data along with high-density lipoprotein cholesterol (HDL-C) and low-density lipopro...
Autores principales: | Friedrich, S, Kastelein, J J P, James, D, Waterhouse, T, Nissen, S E, Nicholls, S J, Krueger, K A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910017/ https://www.ncbi.nlm.nih.gov/pubmed/24452615 http://dx.doi.org/10.1038/psp.2013.70 |
Ejemplares similares
-
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016) -
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects
por: Small, David S., et al.
Publicado: (2016) -
Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection
por: Engwerda, Elsemiek E. C., et al.
Publicado: (2017) -
Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats
por: Roche‐Catholy, Marine, et al.
Publicado: (2022) -
CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015)